More Neuren Pharmaceuticals Limited news
Neuren Pharmaceuticals LimitedASX: NEU

S&P DJI Announces September 2023 Quarterly Rebalance

Sep 1, 2023 at 7:23 AM EDT · Issued by Neuren Pharmaceuticals Limited

Filed with ASX · Sep 1, 2023 at 7:23 AM EDT · 4 pages · English

On 6ix: 6ix.com/news/sandp-dji-announces-september-2023-quarterly-rebalance-5

Neuren Pharmaceuticals Limited on 6ix

Story so far

  • S&P DJI Announces September 2022 Quarterly RebalanceSep 2, 2022
  • S&P DJI Announces March 2022 Quarterly RebalanceMar 4, 2022
  • S&P DJI Announces March 2021 Quarterly RebalanceMar 12, 2021

Earlier from Neuren Pharmaceuticals

  • Q2 2023 quarterly activity and cash flow reportJul 30, 2023
  • Neuren receives US$100m for expanded DAYBUE agreementJul 27, 2023
  • Neuren and Acadia expand global partnership for trofinetideJul 13, 2023
  • Neuren completes enrolment in Phelan-McDermid Phase 2 trialJun 29, 2023
  • Neuren opens first site in US for Prader-Willi Phase 2 trialJun 28, 2023

Later from Neuren Pharmaceuticals

  • Q3 2023 quarterly activity and cash flow reportOct 19, 2023
  • DAYBUE net sales US$66.9 million in Q3 2023Nov 2, 2023
  • Neuren completes enrolment in Pitt Hopkins Phase 2 trialDec 4, 2023
  • P2 trial shows significant improvements in Phelan-McDermidDec 17, 2023
  • Investor presentation, 18 December 2023Dec 17, 2023
All Neuren Pharmaceuticals news releases↗

Follow Neuren Pharmaceuticals into a list and get an email when it puts out news.

Follow Neuren Pharmaceuticals
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer